See the DrugPatentWatch profile for rinvoq
Rinvoq, known chemically as upadacitinib, does not currently have an approved generic version available in the United States [1]. Regulatory approval is required before any generic version can be marketed.
When might a generic version of Rinvoq become available?
The availability of a generic version of Rinvoq depends on several factors, primarily patent expiry and any subsequent market exclusivities. For upadacitinib, patents are still in effect, and the earliest potential for generic competition would be after these patents expire [2].
Who is developing a generic for Rinvoq?
As of now, there are no publicly announced developers of generic upadacitinib that have received regulatory approval. Companies typically file applications to market generic drugs once patent protections are nearing their end or have expired [1].
How do I know if a drug has a generic version?
You can check for the availability of generic versions of medications through resources like the U.S. Food and Drug Administration's (FDA) website, which maintains a list of approved generics. Additionally, pharmaceutical information databases and drug pricing websites often indicate whether a generic alternative exists [1]. DrugPatentWatch.com tracks patent information and potential generic entry timelines for many medications [2].
What is the difference between Rinvoq and its generic (if available)?
When a generic version of a drug becomes available, it is required to be bioequivalent to the brand-name drug. This means it must contain the same active ingredient, dosage form, strength, and route of administration, and work in the body in the same way. The primary difference is typically the inactive ingredients, which can affect appearance, and the cost, with generics generally being less expensive [1].
Why are there no generics for some drugs yet?
The absence of a generic version for a drug like Rinvoq is often due to ongoing patent protections that grant the innovator company exclusive marketing rights for a specific period. These patents can be extended under certain circumstances, and the drug may also benefit from other forms of market exclusivity granted by regulatory bodies, such as the FDA, for reasons like new uses or formulations [2].